1H-Pyrazol

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
28Systemic amyloidosis7
46Malignant rheumatoid arthritis12
IDDisease name (Link within this page)Number of trials
75Cushing disease14
154Epilepsy with continuous spikes and waves during slow sleep2

2. Amyotrophic lateral sclerosis


Clinical trials : 786Drugs : 550 - (DrugBank : 182) / Drug target genes : 170 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

28. Systemic amyloidosis


Clinical trials : 335Drugs : 274 - (DrugBank : 86) / Drug target genes : 47 - Drug target pathways : 165 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,543Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

75. Cushing disease


Clinical trials : 225Drugs : 167 - (DrugBank : 49) / Drug target genes : 65 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

154. Epilepsy with continuous spikes and waves during slow sleep


Clinical trials : 8Drugs : 2 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries